The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function

1995 ◽  
Vol 49 (3) ◽  
Author(s):  
M. Kentsch ◽  
G. M�ller-Esch ◽  
W. Otter ◽  
K. Theisen ◽  
C. Drummer ◽  
...  
Keyword(s):  
Left Ventricular Function ◽  
Calcium Channel ◽  
Ventricular Function ◽  
Calcium Channel Blocker ◽  
Cyclic Gmp ◽  
Channel Blocker ◽  
Left Ventricular ◽  
Impaired Left Ventricular Function ◽  
Dihydropyridine Calcium Channel Blocker ◽  
Exercise Induced

Hemodynamic effects of fructose 1,6-diphosphate in patients with normal and impaired left ventricular function

1997 ◽  
Vol 133 (5) ◽  
pp. 541-549 ◽  
Author(s):  
Angel K. Markov ◽  
Michael A. Brumley ◽  
Alfredo Figueroa ◽  
Thomas N. Skelton ◽  
Patrick H. Lehan
Keyword(s):  
Left Ventricular Function ◽  
Ventricular Function ◽  
Left Ventricular ◽  
Impaired Left Ventricular Function ◽  
Hemodynamic Effects

scholarly journals Effect of Dihydropyridine Calcium-Channel Blocker on Adverse Aortic Events After Thoracic Endovascular Aortic Repair for Type B Aortic Dissection

2021 ◽  
Author(s):  
Fan Yang ◽  
Lyufan Chen ◽  
Jitao Liu ◽  
Songyuan Luo ◽  
Caiyun He ◽  
...  
Keyword(s):  
Propensity Score ◽  
Aortic Dissection ◽  
Calcium Channel ◽  
Propensity Score Matching ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Thoracic Endovascular Aortic Repair ◽  
Type B ◽  
Type B Aortic Dissection ◽  
Dihydropyridine Calcium Channel Blocker

Abstract Objectives: This study aimed to evaluate the effect of dihydropyridine calcium-channel blocker (CCB) on adverse aortic events (AAE) in patients undergoing thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD). Methods: A retrospective study was conducted on patients undergoing TEVAR of TBAD from January 2010 to December 2017 in our center. Patients were divided into CCB group and non-CCB group according to the postoperative dihydropyridine CCB use. AAE including aorta-relative mortality and reintervention, were compared between these two groups. Propensity score matching analysis was performed to avoid the potential effect of known confounders.Results: Before matching, the study cohort comprised 548 patients, including 435 (79.4%) and 113 (20.6%) patients in the CCB and non-CCB groups, respectively. After matching, 101 patients in each group were eligible for the analysis. In the unmatched cohort, AAE occurred in 52 (12.0%) and 29 (25.7%) patients in the CCB and non-CCB groups, respectively (P < 0.001). In the matched cohort, AAE occurred in 8 (7.9%) and 22 (21.8%) patients in the CCB and non-CCB groups, respectively (P = 0.013). Log-rank test analysis revealed that the levels of freedom from AAE were significantly different between the 2 groups in both the unmatched and matched cohorts (P < 0.001 and P = 0.007, respectively). Multivariable analysis showed that CCB use (hazard ratio 0.50, 95% confidence interval 0.32–0.80; P = 0.003) was associated with a lower AAE rate after adjustment for other variables, and was minimally changed after the propensity score matching (HR 0.34, 95% CI 0.15–0.75; P = 0.008).Conclusions: Postoperative dihydropyridine CCB use is protective in patients undergoing TEVAR for acute and sub-acute TBAD.

Sign in / Sign up

Export Citation Format

Share Document